No. Roughly two-thirds of adults under 50 carry herpes simplex virus type 1 (HSV-1) worldwide, and about 13 percent carry HSV-2, so a large share of people carry no herpes simplex virus at all. The remaining eight human herpesviruses are similarly uneven: some are near-universal, others uncommon. "Everyone has herpes" conflates nine distinct viruses with very different biology.

The confusion is understandable. Herpesviruses are masters of latency, and most infections are silent. But "common" is not "universal," and the differences between these viruses matter for diagnosis, treatment, and risk. This explainer walks through the mechanisms, the actual prevalence numbers, the exceptions, and the practical limits of what testing can tell you.

Mechanism: Why Herpesviruses Persist for Life

All herpesviruses share a strategy: after primary infection, the virus enters a dormant state inside specific host cells and reactivates intermittently. This is why antibodies, once present, stay present for life. The virus is not cleared; it is contained.

For HSV-1 and HSV-2, latency occurs in sensory neurons of the trigeminal or sacral ganglia. During latency, viral DNA persists as a circular episome with almost no protein production, which is why the immune system cannot eliminate it. Reactivation is triggered by stress, ultraviolet light, fever, menstruation, or immunosuppression, and the virus travels back down the axon to the skin or mucosa.

The other herpesviruses use different reservoir cells. Epstein-Barr virus (EBV) latently infects B lymphocytes. Cytomegalovirus (CMV) persists in myeloid progenitor cells. Varicella-zoster virus (VZV) hides in dorsal root ganglia and reactivates as shingles decades later. Human herpesvirus 6 (HHV-6) integrates into chromosomal DNA in a small fraction of people, a phenomenon called inherited chromosomally integrated HHV-6. Human herpesvirus 8 (HHV-8, also called KSHV) latently infects B cells and endothelial cells.

The key point: latency is universal among herpesviruses, but infection is not. A virus that persists for life in its host says nothing about how many hosts it reaches.

Quantified Context: How Common Is Each Herpesvirus?

Prevalence varies enormously by virus, age, geography, and behavior. The table below summarizes approximate global or US figures from authoritative surveillance. Ranges reflect real variation across regions and populations.

Virus Common name Approx. adult prevalence Typical primary infection Latent reservoir
HSV-1 Oral/cold sore herpes ~64% globally under 50 (WHO) Childhood, often asymptomatic Trigeminal sensory ganglia
HSV-2 Genital herpes ~13% globally ages 15-49 (WHO) Adolescence/adulthood, sexual Sacral sensory ganglia
VZV Chickenpox/shingles >90% of adults in temperate countries Childhood Dorsal root ganglia
EBV Infectious mononucleosis ~90-95% of adults worldwide Childhood or adolescence B lymphocytes
CMV Cytomegalovirus ~50-60% of US adults; >80% in many low-income regions Often childhood Myeloid progenitors
HHV-6 Roseola Near-universal by age 2 Infancy T cells, monocytes
HHV-7 Roseola (less common cause) ~95% by adulthood Early childhood T cells
HHV-8 Kaposi sarcoma herpesvirus ~2-5% in US; 20-50% in parts of sub-Saharan Africa Adulthood, saliva B cells, endothelial cells

The counterintuitive detail: HSV-1 prevalence is falling in many high-income countries. US serosurveys showed HSV-1 prevalence in adolescents declining from roughly 40 percent to about 30 percent over recent decades, likely due to less childhood exposure. HSV-2 prevalence in the US has also declined modestly. So "everyone has herpes" is becoming less true over time, not more.

A plain-language summary: oral herpes is very common, genital herpes is common but far from universal, and several herpesviruses are nearly universal by adulthood, but HSV-8 and HSV-2 are clearly not.

Edge Cases: Who Genuinely Lacks These Viruses, and Why It Matters

Several populations are genuinely herpes-negative, and identifying them has clinical consequences.

Newborns are almost always HSV-negative at birth unless exposed perinatally. Neonatal HSV infection is rare (roughly 1 in 2,500 to 1 in 10,000 live births in the US) but severe, with high mortality if untreated. This is why mothers with active genital lesions at delivery may be offered cesarean section.

Seronegative adults exist in substantial numbers. Roughly a third of US adults lack HSV-1 antibodies, and about 80-85 percent lack HSV-2. Among people who report no history of genital herpes, most HSV-2 infections are unrecognized, which is a different problem: undiagnosed infection, not absent infection.

Inherited chromosomally integrated HHV-6 affects roughly 1 percent of people and produces persistently high viral loads on blood tests without active disease, a genuine diagnostic pitfall.

Immunocompromised people are an edge case in the opposite direction. Solid-organ transplant recipients and people with advanced HIV can reactivate latent viruses at high rates, and HSV, CMV, and HHV-8 cause disproportionate disease in these groups. A negative antibody test does not guarantee absence of virus in a person with profound immunosuppression, but it usually predicts lower reactivation risk.

Misconceptions: What "Having Herpes" Does and Does Not Mean

The single biggest misconception is that herpes simplex means visible sores. Most HSV-1 and HSV-2 infections are asymptomatic or unrecognized. The WHO estimates that the large majority of HSV-2 infections are never diagnosed. Silent shedding occurs even without symptoms, which is how transmission happens without obvious lesions.

The second misconception is that all herpesviruses are sexually transmitted. HSV-1 is usually acquired in childhood through nonsexual contact. EBV spreads through saliva. VZV spreads through respiratory droplets. CMV spreads through saliva, urine, and breast milk. Only HSV-2 is predominantly sexual, and even that is not exclusively so.

A third misconception is that a positive blood test means you have an active problem. IgG antibodies indicate past infection, not current disease. HSV PCR or viral culture is needed to confirm active lesions. Many clinicians do not recommend routine HSV-2 serology in asymptomatic people because of false positives and psychological harm.

A fourth misconception is that "dormant" means "gone." Latency is lifelong, but reactivation frequency varies widely. Some people shed virus frequently with no symptoms; others never have a recognizable recurrence.

A professional caveat: HSV-1 and HSV-2 antibody tests have imperfect specificity, especially in low-prevalence populations. A positive result in someone with no risk factors should be interpreted with caution and confirmed with a second assay if it changes management.

Practical Actions: What to Do With This Information

Concrete steps depend on your situation, but several thresholds are worth knowing.

If you have recurrent painful sores, particularly around the mouth or genitals, see a clinician and ask for PCR testing of an active lesion within 48 hours of onset, when yield is highest. If you are pregnant and have a history of genital herpes, tell your obstetric provider. Suppressive antiviral therapy in late pregnancy reduces recurrence and transmission risk; discuss timing with your clinician. If you are considering HSV-2 serology without symptoms, know that guidelines from the US Preventive Services Task Force recommend against routine screening in asymptomatic adults, because benefits do not clearly outweigh harms. If you are immunocompromised, ask your care team about CMV and HSV monitoring, since reactivation risk is elevated and prophylaxis may be indicated. If you have a positive HHV-6 test without symptoms, ask whether inherited chromosomal integration could explain it before accepting a diagnosis of active infection.

Red flags that warrant prompt evaluation:

A newborn with vesicles, lethargy, or poor feeding. Genital lesions plus systemic symptoms such as fever or severe pain. Eye pain, redness, or visual change with a history of cold sores, which can signal ocular HSV. Shingles-like rash in a person under 50, which may prompt evaluation for immune dysfunction. Persistent fever or lymphadenopathy in an immunocompromised person.

Limitations: What the Evidence Cannot Tell You

Prevalence estimates are only as good as the surveys behind them, and they vary by region, age group, and testing method. WHO global figures rely on modeled estimates from serosurveys, not universal testing. US figures come from NHANES, which samples the civilian noninstitutionalized population and may not represent people in institutions or certain high-risk groups.

Antibody tests cannot distinguish HSV-1 from HSV-2 perfectly, and cross-reactivity occurs. They also cannot tell you when infection occurred or how often you shed virus. Viral culture is declining in use because PCR is more sensitive and faster.

No vaccine is currently approved for HSV-1 or HSV-2. Research is ongoing, but no product has met efficacy endpoints in large trials. This limits prevention to behavioral measures and antiviral suppression for known cases.

Finally, the exact share of people who carry zero herpesviruses is not directly measured. It can only be inferred by combining prevalence figures for each virus, and those figures are not independent: people with one infection are more likely to have others, so simple multiplication overestimates how many people are truly virus-free. The honest answer is that a meaningful minority carries no HSV at all, while most adults carry at least one herpesvirus, usually EBV or HSV-1.